Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients: A Prospective, Multicenter, Randomized, Open-label, Controlled Phase III Study

Trial Profile

Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients: A Prospective, Multicenter, Randomized, Open-label, Controlled Phase III Study

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Rifaximin (Primary) ; Ciprofloxacin
  • Indications Bacterial peritonitis
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 24 Apr 2017 Status changed from recruiting to withdrawn prior to enrolment.
    • 01 Dec 2014 Status changed from not yet recruiting to recruiting as per ClinicalTrial.gov record.
    • 22 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top